TY - JOUR
T1 - Mesenchymal stem cells for sensorineural hearing loss
T2 - a systematic review of preclinical studies
AU - Chorath, Kevin
AU - Willis, Matthew
AU - Morton-Gonzaba, Nicolas
AU - Moreira, Alvaro
N1 - Publisher Copyright:
© 2020, Springer Nature B.V.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Sensorineural hearing loss (SNHL) is the most common form of hearing loss that is routinely treated with hearing aids or cochlear implants. Advances in regenerative medicine have now led to animal studies examining the possibility of restoring injured hair cells with mesenchymal stem/stromal cell (MSC) administration. We conducted a systematic review and meta-analysis to collate the existing preclinical literature evaluating MSCs as a treatment for SNHL and quantify the effect of MSCs on functional hearing. Our protocol was published online on CAMARADES. Searches were conducted in four medical databases by two independent investigators. Twelve studies met inclusion and were evaluated for risk of bias using SYRCLE. Rodent models were commonly used (n = 8, 66%), while auditory brainstem response (ABR) and distortion product otoacoustic emissions (DPOAE) were the most frequent measures assessing hearing loss. MSCs were derived from multiple tissue sources, including bone marrow, adipose tissue, and umbilical cord blood and the dose ranged from 4 × 103 to 1 × 107 cells. Treatment with MSCs resulted in an improvement in ABR and DPOAE (mean difference-15.22, + 9.10, respectively). Despite high heterogeneity and multiple “unclear” domains in the risk of bias, this review provides evidence that MSCs may have a beneficial effect in hearing function.
AB - Sensorineural hearing loss (SNHL) is the most common form of hearing loss that is routinely treated with hearing aids or cochlear implants. Advances in regenerative medicine have now led to animal studies examining the possibility of restoring injured hair cells with mesenchymal stem/stromal cell (MSC) administration. We conducted a systematic review and meta-analysis to collate the existing preclinical literature evaluating MSCs as a treatment for SNHL and quantify the effect of MSCs on functional hearing. Our protocol was published online on CAMARADES. Searches were conducted in four medical databases by two independent investigators. Twelve studies met inclusion and were evaluated for risk of bias using SYRCLE. Rodent models were commonly used (n = 8, 66%), while auditory brainstem response (ABR) and distortion product otoacoustic emissions (DPOAE) were the most frequent measures assessing hearing loss. MSCs were derived from multiple tissue sources, including bone marrow, adipose tissue, and umbilical cord blood and the dose ranged from 4 × 103 to 1 × 107 cells. Treatment with MSCs resulted in an improvement in ABR and DPOAE (mean difference-15.22, + 9.10, respectively). Despite high heterogeneity and multiple “unclear” domains in the risk of bias, this review provides evidence that MSCs may have a beneficial effect in hearing function.
KW - Animal models
KW - Mesenchymal stem cells
KW - Meta-analysis
KW - Preclinical
KW - Risk of bias
KW - Sensorineural hearing loss
KW - Stem cells
KW - Systematic reviews
UR - http://www.scopus.com/inward/record.url?scp=85084089881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084089881&partnerID=8YFLogxK
U2 - 10.1007/s11033-020-05460-0
DO - 10.1007/s11033-020-05460-0
M3 - Review article
C2 - 32323262
AN - SCOPUS:85084089881
SN - 0301-4851
VL - 47
SP - 4723
EP - 4736
JO - Molecular Biology Reports
JF - Molecular Biology Reports
IS - 6
ER -